Blood-Pressure-Lowering Characteristics of Antihypertensive Drugs

2015 ◽  
pp. 91-108
Keyword(s):  
Blood Pressure ◽  
Antihypertensive Drugs ◽  
Blood Pressure Lowering ◽  
Pressure Lowering

scholarly journals Emerging Drug Classes and Their Potential Use in Hypertension

Hypertension ◽  
2019 ◽  
Vol 74 (5) ◽  
pp. 1075-1083 ◽  
Author(s):  
Michel Azizi ◽  
Patrick Rossignol ◽  
Jean-Sébastien Hulot
Keyword(s):  
Blood Pressure ◽  
Antihypertensive Drugs ◽  
Generic Drugs ◽  
Antihypertensive Agents ◽  
Uncontrolled Hypertension ◽  
Blood Pressure Lowering ◽  
Receptor Antagonists ◽  
Drug Classes ◽  
Pressure Lowering ◽  
Potential Use

Despite the availability of multiple antihypertensive drugs targeting the different pathways implicated in its pathophysiology, hypertension remains poorly controlled worldwide, and its prevalence is increasing because of the aging of the population and the obesity epidemic. Although nonadherence to treatment contributes to uncontrolled hypertension, it is likely that not all the pathophysiological mechanisms are neutralized by the various classes of antihypertensive treatment currently available, and, the counter-regulatory mechanisms triggered by these treatments may decrease their blood pressure–lowering effect. The development of new antihypertensive drugs acting on new targets, with different modes of action, therefore, remains essential, to improve blood pressure control and reduce the residual burden of cardiovascular risks further. However, the difficulties encountered in the conception, development, costs, and delivery to the market of new classes of antihypertensive agents highlights the hurdles that must be overcome to release and to evaluate their long-term safety and efficacy for hypertension only, especially because of the market pressure of cheap generic drugs. New chemical entities with blood pressure–lowering efficacy are thus being developed more for heart failure or diabetic kidney disease, 2 diseases pathophysiologically associated with hypertension. These include dual angiotensin II receptor-neprilysin inhibitors, soluble guanylate cyclase stimulators, nonsteroidal dihydropyridine-based mineralocorticoid receptor antagonists, as well as sodium-glucose cotransporter 2 inhibitors. However, centrally acting aminopeptidase A inhibitors and endothelin receptor antagonists have a dedicated program of development for hypertension. All these emergent drug classes and their potential use in hypertension are reviewed here.

Antitrophic properties of antihypertensive drugs may depend solely on their blood pressure-lowering capability

1989 ◽  
Vol 86 (4) ◽  
pp. 67-69 ◽  
Author(s):  
Helle Nielsen ◽  
Hanne R.L. Christensen ◽  
Kent L. Christensen ◽  
Ulrik Baandrup ◽  
Lennard T. Jespersen
Keyword(s):  
Blood Pressure ◽  
Antihypertensive Drugs ◽  
Blood Pressure Lowering ◽  
Pressure Lowering

scholarly journals Evaluation of blood pressure lowering effect by generic and brand-name antihypertensive drugs treatment

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Shu-Yuan Zhang ◽  
Li-Yuan Tao ◽  
Yun-Yun Yang ◽  
Tao Kong ◽  
Cun-Jin Wu ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Antihypertensive Drugs ◽  
Brand Name ◽  
Blood Pressure Lowering ◽  
Blood Pressure Lowering Effect ◽  
Lowering Effect ◽  
Pressure Lowering

Lessons from the novel renoprotective studies made by antihypertensive drugs

2013 ◽  
Vol 154 (7) ◽  
pp. 243-247 ◽  
Author(s):  
László Bajnok
Keyword(s):  
Blood Pressure ◽  
Renal Function ◽  
Antihypertensive Drugs ◽  
Surrogate Endpoint ◽  
The Novel ◽  
Blood Pressure Lowering ◽  
Optimum Point ◽  
J Curve ◽  
Pressure Lowering ◽  
Therapeutic Measures

From the evaluated ONTARGET, ALTITUDE, ACCOMPLISH, ROADMAP, and ACCORD-BP studies a conclusion can be drawn that though microalbuminuria/proteinuria is a strong epidemiological biomarker, in interventional studies it is not necessarily a reliable surrogate endpoint as actual renal function may change in an opposite way. Namely, some therapeutic measures improving microalbuminuria/proteinuria may actually worsen renal function. In case of procedures such as blood pressure lowering or measure of RAS blockade an optimum point on a J-curve may exist. Orv. Hetil., 2013, 154, 243–247.

Sign in / Sign up

Export Citation Format

Share Document